TT 173

Drug Profile

TT 173

Alternative Names: TT-103; TT-103MH; TT-173; Yeast-derived microvesicles containing recombinant Tissue Factor

Latest Information Update: 24 Dec 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Thrombotargets Corporation
  • Class Antihaemorrhagics; Recombinant proteins
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Von Willebrand disease; Haemophilia
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II/III Blood coagulation disorders

Most Recent Events

  • 09 Dec 2015 Phase-II/III clinical trials in Coagulation disorders in Spain (Topical, Powder) (EudraCT2015-003408-21)
  • 04 Oct 2013 Phase-II clinical trials in Coagulation disorders in Spain (Topical)
  • 01 Sep 2013 Thrombotargets completes a phase I trial for Coagulation disorders in Spain (NCT01595360)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top